[Calcium channel blockers and atherosclerosis].
As changes in the calcium transport mechanisms contribute to cellular changes in atherosclerosis, it has been proposed that calcium channel blocker (CCB) may be effective in slowing the progression of coronary artery disease. CCBs possess anti-oxidative properties and protective effects on vascular cells. Randomized clinical trials including PREVENT and ELSA may establish a potentially new therapeutic role for third-generation dihydropyridinoline CCBs in the treatment of atherosclerosis.
Hirata
Ken-ichi
K
Division of Cardiovascular and Respiratory Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
Yokoyama
Mitsuhiro
M
D000818:Animals; D001161:Arteriosclerosis / Q000188:drug therapy*; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D003327:Coronary Disease / Q000188:drug therapy; D006801:Humans; D016032:Randomized Controlled Trials as Topic
D002121:Calcium Channel Blockers